Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974736 · ClinicalTrials.gov registry record · NA
eCEASE to Support Treatment for Parental Tobacco Use
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 817
- Enrollment target
NCT04974736: Completed NA study, sponsored by Massachusetts General Hospital.
NCT04974736 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 817 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04974736, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 817 participants
- Enrollment target
Study Summary
The proposed project aims to develop an innovative and disseminable electronic health record (iEHR)-based approach that supports optimal primary care workflows to routinely screen families for tobacco and e-cigarette use, address household smoking behavior and promote smoke-free and e-cigarette free home and car rules in a routine and effective manner in the pediatric setting. Additionally, parents enrolled in the study will be offered assistance by a community health navigator (CHN). This study aims to examine how effective the iEHR + Navigator strategy is compared to usual care control.
Primary Outcome
Parental 7-day combusted tobacco quit rates, as assessed by validated surveys, biochemically confirmed at 12 months between the intervention \& usual care arms
Interventions
- BEHAVIORAL iEHR + Navigator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 817 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2024-08-15 |
| Phase | NA |
What the finished NCT04974736 record still lists
NCT04974736 is an interventional study that assigns participants to a tested intervention. The registered 817 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 1 intervention - of which iEHR + Navigator is the first listed.
NCT04974736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04974736 about?
NCT04974736 is a clinical study titled "eCEASE to Support Treatment for Parental Tobacco Use". The proposed project aims to develop an innovative and disseminable electronic health record (iEHR)-based approach that supports optimal primary care workflows to routinely screen families for tobacco and e-cigarette use, address household smoking behavior and promote smoke-free and e-cigarette free...
What is the current status of trial NCT04974736?
This trial is currently completed. It is a NA study. The enrollment target is 817 participants. The study started on 2021-07-16. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT04974736?
The interventions under investigation include: iEHR + Navigator (BEHAVIORAL).
Who is sponsoring clinical trial NCT04974736?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04974736's enrollment target sits among peer trials
817 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI